Olympus FY3/26 Results Beat Expectations, GIS Business Strong, FDA Corrective Actions Progressing Positively, Maintain Buy

Overview

This report summarizes key points from Goldman Sachs' May 28, 2026 investor call on Olympus (7733.T). The report notes the company's FY3/26 full-year results exceeding expectations, particularly in Gastrointestinal Solutions (GIS) business; meanwhile, FY3/27 outlook projects year-on-year revenue and margin growth; addressing issues identified in prior FDA inspections, the company has submitted corrective action plans and continues to advance quality improvement initiatives. Based on these positive developments, Goldman Sachs maintains its 'Buy' rating and 12-month target price of 2050 JPY.

Core views

Olympus FY3/26 Q4 sales performance strong, particularly in North American GIS business, primarily due to resolution of EDOF endoscopy supply shortage; European market also showed significant growth, benefiting from UK budget execution and large orders in France and Nordic regions. Full-year operating profit exceeded revised Q3 guidance, driven by sales beating expectations, lower-than-expected one-time costs (e.g., early retirement plan expenses, development asset impairment), and gains from the sale of a building in Europe. Looking ahead to FY3/27, the company expects year-on-year revenue growth and margin improvement, but two key variables need monitoring: first, the timing of product sales recovery affected by voluntary suspension, estimated to impact FY3/27 revenue by 27 billion JPY (2/3 in H1), primarily in Surgical Intervention Solutions (SIS) business; second, China market performance, though challenging, local manufacturing (gastric processors and endoscopes already launched, colon endoscopes planned for FY3/27 H1 launch) is expected to drive incremental growth. Regionally, North America and Europe continue steady growth, Japan domestic market remains under pressure, China in transition and investment phase. Regarding FDA, the company completed responses to eight global site inspections by end-2025, submitted the full corrective action plan to FDA, Aizu factory re-inspection date not yet determined, but 'Elevate' quality improvement project largely completed in FY3/26, with related costs expected to decline significantly from FY3/27.

Analysis framework

Goldman Sachs employs a four-step analytical framework: performance validation – forward guidance – key variable decomposition – regulatory risk tracking. First, confirm structural reasons for FY3/26 results exceeding expectations (GIS regional sales + cost optimization); second, anchor FY3/27 growth expectations and identify core variables affecting achievement (suspension recovery pace, China business progress); third, decompose growth drivers and pressure sources by region to clarify underlying market-specific performance logic (e.g., North American inventory restocking, European large orders, Japan product cycle end); fourth, view FDA regulatory progress as a key non-financial catalyst, focusing on three-stage evolution path: corrective actions (plan submission, project implementation), cost inflection point (Elevate cost decline), and final goal (warning letter removal). In valuation, Goldman Sachs uses relative EV/EBITDA valuation method, benchmarking against global medical device industry's FY3/28 expected average EV/EBITDA multiple of 11.0x, applying 10% discount to derive target multiple of 9.9x, and deriving 2050 JPY target price, reflecting prudent consideration of FDA regulatory risks and slowing Japan market growth.

Methodology notes

• Valuation MethodEV/EBITDA valuation

  Using comparable company EV/EBITDA multiples as a benchmark, adjusted for industry and company-specific factors to derive target price

  This method is suitable for capital-intensive, cash-flow-stable manufacturing companies, effectively isolating capital structure and tax differences; Goldman Sachs applies 10% discount to reflect Olympus' FDA regulatory risks and sluggish Japan domestic growth.

• Industry/Industry Analysis FrameworkSupply-demand framework

  Decomposing core medical device industry contradictions into supply side (capacity, compliance, supply chain) and demand side (hospital budgets, procurement cycles, clinical penetration)

  Analysis of North American EDOF supply recovery, European large order execution, Japan product lifecycle, and China localization in the report all revolves around matching supply capacity release with regional demand rhythm, which is key to understanding earnings volatility.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• Olympus (7733.T)

  Core coverage stock, directly benefiting from GIS business growth, FDA corrective actions, and China localization ramp-up

  Strengths

  Global endoscopy leader, GIS business with high technological barriers and strong customer stickiness; quality system upgrade (Elevate project) has shown results

  Weaknesses

  Japan domestic growth lackluster, product cycle entering end phase; SIS business significantly impacted by FDA suspension, short-term pressure

  Comparison

  Compared to peers, GIS business maintains stable market share in North America and Europe, but faces strong competition in SIS segment; China localization progress leads some international competitors

  Risks

  FDA warning letter resolution progress below expectations; Chinese market demand recovery slower than expected; unexpected yen appreciation eroding overseas profits

Key data

• FY3/26 full-year operating profitExceeded revised Q3 guidancePrimarily due to sales beating expectations and lower-than-expected one-time costs
• FY3/27 sales impact (suspension)27 billion JPYPrimarily impacting Surgical Intervention Solutions (SIS) business, H1 accounting for approximately 2/3
• 12-month target price2050 JPYCalculated based on global medical device industry FY3/28 EV/EBITDA of 11.0x, with 10% discount applied
• Current share price (May 29, 2026 close)1786 JPYCorresponding to implied upside of 14.8%

Impact & implications

This teleconference reinforces Olympus' earnings recovery certainty, particularly validating the competitiveness of GIS, its core business, across major global markets. If FY3/27 growth guidance is met as expected, combined with gradual resolution of FDA regulatory risks, the company is poised for valuation re-rating. For the Chinese market, localization production is not only a measure to address trade and compliance risks but also a key lever to unlock incremental growth; Japan domestic sales stability hinges on the launch pace of the next-generation endoscopy platform and hospital budget recovery.

Risks

• Global regulatory policy changes (especially FDA tightening medical device approval and inspection standards)
• Continued pressure on China medical device market operating environment, affecting localization product ramp-up pace
• Recurring infectious disease outbreaks potentially disrupting routine hospital procedures and equipment procurement
• Unexpected yen appreciation leading to expanded foreign exchange losses on USD-denominated overseas revenue
• Manufacturing and sales-related risks (e.g., supply chain disruption, rising logistics costs)
• Product development failure or clinical trial progress below expectations

What to watch

• Quarterly sales trends of core GIS business in North America and Europe
• Actual execution progress of margin improvement measures and product portfolio optimization
• FDA feedback on corrective action plan and Aizu factory re-inspection schedule
• Actual installation and usage feedback of gastric/colon endoscopes from China localization production